Skip to main content
INCY
NASDAQ Life Sciences

EU Approves Incyte's Opzelura as First Steroid-Free Topical JAK for Atopic Dermatitis

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$119
Mkt Cap
$25.958B
52W Low
$69.695
52W High
$132.6
52W Position info
71% above low
Off High info
10% below high
Rel. Volume info
3.3× avg
Market data snapshot near publication time

INCY sits 71% above its 52-week low of $69.695 on elevated volume (3.3× avg).

Summary

The European Commission approved Opzelura cream for moderate atopic dermatitis in adults, making it the first steroid-free topical JAK inhibitor cleared for this indication in the EU. The approval expands Opzelura's European label beyond non-segmental vitiligo and opens a market where up to 7% of adults are affected. It follows a positive CHMP opinion in June and is supported by Phase 3b data showing significant itch relief as early as Day 2 and durable responses through 24 weeks. This comes on the heels of Incyte's strong Q2 report and raised guidance, adding a new growth driver in Europe. The company now has two approved indications for Opzelura in the EU, strengthening its dermatology franchise.

Updates

  1. · Wiseek News — Analysts at Guggenheim, HC Wainwright, Barclays, and Leerink raised price targets to $139–$155 following the approval.

At the time of this announcement, INCY was trading at $119.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $69.70 to $132.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

INCY - Latest Insights

INCY
Oct 29, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $116.80
Real-time Price: $121.13 info
Change: +$4.33 (+4%) info
Market Cap: $24.719B info
INCY
Oct 29, 2026, 11:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $115.20
Real-time Price: $121.13 info
Change: +$5.93 (+5%) info
Market Cap: $24.719B info
INCY
Oct 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.76
Real-time Price: $121.13 info
Change: +$3.37 (+3%) info
Market Cap: $24.719B info
INCY
Aug 31, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $123.22
Real-time Price: $121.13 info
Change: -$2.09 (-2%) info
Market Cap: $24.719B info
INCY
Jul 29, 2026, 4:36 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $119.00
Real-time Price: $121.13 info
Change: +$2.13 (+2%) info
Market Cap: $24.719B info